Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...
On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important ...
COEPTIS, Inc. has established GEAR Therapeutics as a majority-owned subsidiary to advance its GEAR-modified natural killer (NK) cell therapy into first-in-human studies targeting various cancers and ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...
Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumoursOslo, Norway, 17 December ...
Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable ...
Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today ...
Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...
On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important step in developing scalable and accessible 'off-the-shelf' cell therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback